Diabetic Macular Edema Epidemiology Analysis and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
In the 7MM total prevalent cases of diabetic macular edema epidemiology were 1,724,733 in 2021. The cases are expected to grow at an AGR of more than 1% during 2021-2031. Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The pathogenesis of ME is complex and multifactorial and mainly results from the disruption of the blood-retinal barrier, leading to the accumulation of fluid and serum macromolecules in the intercellular space.
DME market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of DME. The diagnosed prevalent cases of DME are further segmented by age (20 years and older), sex, involvement of the eye (center-involving DME and non-center-involving DME) and by type of DME (focal-pattern DME and diffuse-pattern DME). The following data describes epidemiology of DME.
Diabetic Macular Edema Epidemiology, Outlook
For more insights, download a free report sample
Age-Specific 12-Month Diagnosed Prevalent Cases of DME
The key age segments in the 12-month diagnosed prevalent cases of DME are, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and more than 80. In 2021, for the 7MM combined, adults ages 60–69 years contributed the highest proportion of the diagnosed prevalent cases of DME.
Age-Specific 12-Month Diagnosed Prevalent Cases of DME
For more key age segment insights, download a free report sample
COVID-19 Impact in the DME Epidemiology Market
The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences as global healthcare systems have been redirected to focus on fighting the pandemic. The impact of COVID-19 may include a shortage of medical staff, decreased access to treatment, a delay in diagnosis, decreased survival, and an increase in disease incidence related to coronavirus infections. Intravitreal therapy is widely recognized as a major milestone in ophthalmology, being one of the most commonly performed ocular procedures for DME. The spread of coronavirus disease led to a significant downsizing of non-urgent treatments provided for ocular disorders, including intravitreal therapy.
Market report overview
Market size 2021 | 1,724,733 cases |
AGR% (2021-2031) | >1% |
Key age segments | 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and >80 |
Scope
- The Diabetic Macular Edema (DME) Epidemiology Report and Model provide an overview of the risk factors and global trends of DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME. The diagnosed prevalent cases of DME are further segmented by age (20 years and older), sex, and involvement of the eye (center-involving DME and non-center-involving DME) and by type of DME (focal-pattern DME and diffuse-pattern DME). The model associated with the report also provides the diagnosed prevalent cases of clinically significant DME among the diagnosed DME population.
- The DME epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
- The Diabetic Macular Edema (DME) Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global DME market.
- Quantify patient populations in the global DME market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for DME therapeutics in each of the markets covered.
- Understand magnitude of DME population
Table of Contents
Table
Figures
Frequently asked questions
-
What was the total number of prevalent cases of DME in 2021?
The total number of prevalent cases of DME were 1,724,733 in 2021.
-
What is the growth rate of DME epidemiology market?
The DME epidemiology market is expected to grow at an AGR of more than 1%.
-
What are the age-segments in the DME epidemiology market?
The key age segments in the 12-month diagnosed prevalent cases of DME are 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and more than 80.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.